Quick Answer
Jazz Pharmaceuticals plc reported Revenue From Contract With Customer Excluding Assessed Tax of $4.27 billion for the year ending 2025.
- Jazz Pharmaceuticals plc showed an increase of +4.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Jazz Pharmaceuticals plc's Revenue From Contract With Customer Excluding Assessed Tax has grown by 186.8%.
- Historical annual values: Fiscal year 2025: $4.27 billion | Fiscal year 2024: $4.07 billion | Fiscal year 2023: $3.83 billion | Fiscal year 2022: $3.66 billion | Fiscal year 2021: $3.09 billion | Fiscal year 2020: $2.36 billion | Fiscal year 2019: $2.16 billion | Fiscal year 2018: $1.89 billion | Fiscal year 2017: $1.62 billion | Fiscal year 2016: $1.49 billion.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: